Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer

BACKGROUND: The presence of hypoxia is a poor prognostic factor in prostate cancer and the hypoxic tumor microenvironment promotes radioresistance. There is potential for drug radiotherapy combinations to improve the therapeutic ratio. We aimed to investigate whether hypoxia-associated genes could b...

詳細記述

保存先:
書誌詳細
出版年:BMC Urol
主要な著者: Bibby, Becky A. S., Thiruthaneeswaran, Niluja, Yang, Lingjian, Pereira, Ronnie R., More, Elisabet, McArt, Darragh G., O’Reilly, Paul, Bristow, Robert G., Williams, Kaye J., Choudhury, Ananya, West, Catharine M. L.
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2021
主題:
Research Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8247203/
https://ncbi.nlm.nih.gov/pubmed/34210300
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12894-021-00856-x
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料